Evolus (EOLS) Stock Analysis & AI Equity Report
Evolus (EOLS) overview
Evolus (EOLS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 297m and operating profit of USD -32.7m; the year-end share price was 6.65 USD and market capitalisation was USD 432m. Evolus is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Evolus's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Evolus
Evolus is a global aesthetics company serving licensed aesthetic practitioners in the cash-pay market. Its commercial products include Jeuveau, an injectable botulinum toxin type A for temporary improvement of moderate to severe frown lines in adults, and Evolysse injectable hyaluronic acid gels for wrinkles and folds. The company also describes Evolysse products for facial areas including the mid face, lips and eyes.
Generate the Evolus report
Evolus is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Evolus and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Evolus
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.